` PROK (ProKidney Corp) vs S&P 500 Comparison - Alpha Spread

P
PROK
vs
S&P 500

Over the past 12 months, PROK has significantly outperformed S&P 500, delivering a return of +42% compared to the S&P 500's +19% growth.

Stocks Performance
PROK vs S&P 500

Loading
PROK
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PROK vs S&P 500

Performance Gap Between PROK and GSPC
HIDDEN
Show

Performance By Year
PROK vs S&P 500

Loading
PROK
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
ProKidney Corp vs Peers

S&P 500
PROK
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ProKidney Corp
Glance View

Market Cap
690.9m USD
Industry
Biotechnology

ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 0 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The firm is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The firm is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.

PROK Intrinsic Value
Not Available
Back to Top